Amgen
Compare Amgen…Large-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AmgenLarge-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
Quarterly breakdown of revenue by product line and service category
2021-Q1 — 2025-Q4
Quarterly breakdown of revenue by geographic region
2021-Q1 — 2025-Q4
Data from SEC filings via FMP • 32 periods available